24/7 Market News Snapshot 15 May, 2025 – Autonomix Medical, Inc. Common Stock (NASDAQ:AMIX)

May 15, 2025

DENVER, Colo., 15 May, 2025 (www.247marketnews.com) – (NASDAQ:AMIX) are discussed in this article.
Autonomix Medical, Inc. (AMIX) is currently witnessing a strong upward trajectory in its stock value, trading at $1.812 in the pre-market session, reflecting a notable increase of 4.14% from the previous close of $1.740. The trading volume at 2.18 million shares indicates robust investor interest, suggesting that positive sentiment surrounding the company is likely driven by recent developments. Noteworthy resistance levels are positioned around $1.85, while support may be identified near $1.75. Continued bullish momentum could enhance AMIX’s appeal as a promising investment option for those seeking growth potential.

In tandem with its stock performance, Autonomix is excited to announce a crucial enhancement to its intellectual property with the issuance of U.S. Patent No. 12,257,071, titled “Controlled Sympathectomy and Micro-Ablation Systems and Methods.” This patent highlights the company’s innovative strides in the nerve-mapping and denervation sector, underscoring its commitment to advancing minimally invasive treatments focused on nerve therapies.

The newly issued patent underscores the efficacy of Autonomix’s advanced catheter-based systems that combine nerve mapping with radiofrequency ablation techniques. This integration aims to increase the precision and effectiveness of addressing a variety of nerve-related conditions such as chronic pain and hypertension through minimally invasive strategies.

CEO Brad Hauser articulated the company’s enthusiasm for this achievement, stating, “We are excited to announce the issuance of this patent, as it marks a key development in our strategy to transform pain management and neurology treatments. This innovation is critical in solidifying our position in the rapidly growing nerve-focused therapeutics space and supports our goal of delivering enhanced solutions for both clinicians and patients alike.”

With a growing global patent portfolio now exceeding 80 issued patents and 40 pending applications, Autonomix is determined to remain at the forefront of medical innovation. The company plans to submit an Investigational Device Exemption (IDE) and initiate U.S. clinical trials in 2025, further exemplifying its commitment to revolutionizing treatment options in neurological disorders.

Related news for (AMIX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.